BWXT Medical Executes Commercial Agreement with Bayer for Supply of Actinium-225 Based Products
(OTTAWA, ON – June 27, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has executed a commercial agreement with Bayer AG (Bayer) to supply high-purity Actinium-225 (Ac-225).
BWXT Medical and TRIUMF Execute Agreement for Manufacture of High Purity Ac-225 Based Products
BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. and TRIUMF, Canada’s particle accelerator centre, have executed a licensing and services agreement that strengthens their existing partnership for the production of medical isotopes.